CGEM Average Annual Return Since 2021
Growth of $10,000.00
Without Dividends Reinvested Into CGEM


Also see:
CGEM stock yearly return 2022
CGEM stock yearly return 2023
CGEM YTD return
Compare CGEM average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 01/11/2021
End date: 06/24/2024
Start price/share: $28.00
End price/share: $17.37
Dividends collected/share: $0.00
Total return: -37.96%
CGEM Average Annual Return: -12.93%
Starting investment: $10,000.00
Ending investment: $6,202.80
Years: 3.45


CGEM average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Cullinan Oncology is a biopharmaceutical company. Zipalertinib (CLN-081/TAS6417) which Co. is co-developing with an affiliate of Taiho Pharmaceutical, Co. Ltd (Taiho), is an orally bioavailable small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 insertion (EGFRex20ins) mutations with relative sparing of cells expressing wild-type EGFR. In addition to zipalertinib, Co.'s portfolio includes four other clinical-stage product candidates and one product candidate that is pending the U.S. Food and Drug Administration clearance for its investigational new drug application. The CGEM average annual return since 2021 is shown above.

The Average Annual Return on the CGEM average annual return since 2021 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether CGEM average annual return since 2021 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the CGEM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree CGEM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cullinan Therapeutics (CGEM) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CGEN Average Annual Return
CGTX Average Annual Return
CHE Average Annual Return
CHRS Average Annual Return
CI Average Annual Return
CING Average Annual Return
CKPT Average Annual Return
CLDX Average Annual Return
CLNN Average Annual Return
CLOV Average Annual Return
More Healthcare companies »

 

CGEM Average Annual Return Since 2021 | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.